PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

The Importance of Rater Training in Clinical Trials: A Webinar Focusing on Psychiatric Assessments and eCOA

14 September 2016; 3:00 pm GMT, 10:00 am ET
Register

Rater training is used within clinical trials to improve the consistency and reliability of subjective data collected from patients, caregivers/observers, and clinicians/interviewers. This will review why rater training is so important, as well as what the FDA and EMA have determined regarding rater training and electronic data capture.

As the number and complexity of clinical trials has increased over the years, so too has the difficulty in monitoring and maintaining reliable data collection. Clinical trials often involve multiple sites, frequently across multiple countries, languages and cultures. Reliable data collection depends on consistency among and within the raters collecting data. Use of electronic Clinical Outcome Assessments (eCOA) and rater training for all clinical trial raters whether they are site staff or patients – improves data validity and reliability.

Because of the increase in the use of psychiatric assessments in clinical trials, more people without psychiatric experience are administering these assessments and many assessments rely on self-administration by research subjects, which makes rater training even more critical. Furthermore, it is just as important that raters experienced in psychiatric assessments be trained, as differences in assessment technique introduces significant variability into data.
This webinar will focus on the increased need for psychiatric assessments in clinical trials for indications involving non-psychiatric outcomes, as well as specific psychiatric primary outcomes. You will learn how rater bias, rater errors, and rater variability impact the quality of clinical data. Importantly, you will learn how rater training coupled with eCOA addresses many of the problems that plague clinical trials.
Unreliable data can lead to costly and potentially catastrophic results. Rater training and eCOA reduces poor data quality, improves inter-rater and intra-rater reliability, and reduces sample size while improving power to detect true effects. Join us in learning how to improve the quality of your clinical trials through rater training and eCOA.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026